TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07315061: Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis

Sponsor: InventisBio Co., Ltd · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 222 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT07315061 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07315061 Rescue Dossier →